Why Editas Medicine Stock Was Skyrocketing This Week
The company's CEO made quite the encouraging statement regarding its immediate future.
Editas Medicine ( EDIT ) Reports Q2 Loss, Tops Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of -53.66% and +320.94%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
TScan Therapeutics, Inc. ( TCRX ) Reports Q2 Loss, Beats Revenue Estimates
TScan Therapeutics (TCRX) delivered earnings and revenue surprises of 0.00% and +58.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Can This Beaten-Down Stock Bounce Back?
This small-cap biotech is seeking to develop breakthrough therapies, but so far it's found little success.
Humacyte, Inc. ( HUMA ) Reports Q2 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -60.00% and -73.60%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Are Medical Stocks Lagging Editas Medicine ( EDIT ) This Year?
Here is how Editas Medicine (EDIT) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.
MiMedx ( MDXG ) Q2 Earnings and Revenues Beat Estimates
MiMedx (MDXG) delivered earnings and revenue surprises of +66.67% and +10.45%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
3 Genomics Stocks Worth Adding to Your Portfolio in 2025
CRISPR-based innovators like NTLA, EDIT and PRME are gaining traction as genomics reshapes the future of medicine and biotech ...
Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?
Investors looking for stocks that can produce dramatic gains in a short amount of time will want to turn their heads toward the biopharmaceutical space. Chasing short-term gains isn't the smartest way to invest, but hardly a month goes by without at least one stock from this industry shooting ...
2 Beaten-Down Stocks to Avoid
Over the past year, Editas Medicine ( NASDAQ: EDIT ) and Sarepta Therapeutics ( NASDAQ: SRPT ) , two biotech companies, have encountered severe headwinds that aren't at all related to broader market volatility. Both drugmakers have seen their shares plummet over the trailing-12-month period.
Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst - Eli Lilly ( NYSE:LLY ) , Verve Therapeutics ( NASDAQ:VERV )
Eli Lilly offered a 115% premium for Verve, signaling a major vote of confidence in gene editing platforms. HC Wainwright and William Blair downgraded Verve after the deal. Last Chance: See the "Power Pattern" That Delivered Winners 9 Out of the Last 10 Summers. Get The Details Here
Gene-Editing Stocks Gain on LLY-VERV Deal Announcement
LLY's move to buy Verve ignites investor interest across gene-editing stocks like CRSP, NTLA and BEAM in a booming M&A year.
Editas Medicine Is Great. Here's Why You Shouldn't Buy It.
The biotechnology sector is a thrilling arena for investors, with a history of delivering groundbreaking medical innovations that have led to massive shareholder returns. Editas Medicine ( NASDAQ: EDIT ) is a promising clinical-stage company that has captured Wall Street's attention at the ...
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy.
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June - Editas Medicine ( NASDAQ:EDIT )
Achieved 58% mean editing at five months after a single dose using high efficiency HSC delivery, demonstrating therapeutically relevant editing levels using a clinically validated strategy. Achievement supports development of a novel, in vivo approach to treating sickle cell disease and beta ...
Why Is Editas ( EDIT ) Up 40% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
1 Stock Down 97% That Could Double, According to Wall Street
Over the past few years, investors have moved away from somewhat speculative and unprofitable companies to put their money into safer, steadier investments. Editas Medicine ( NASDAQ: EDIT ) , a gene-editing-focused clinical-stage biotech, is firmly in the speculative camp, which is why its shares ...
Editas Medicine: A Cautionary Tale for Investors
Explore the exciting world of Editas Medicine ( NASDAQ: EDIT ) with our expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities!*Stock prices used were the prices of April 9, 2025.
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy ...
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June - Editas Medicine ( NASDAQ:EDIT )
Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy
EXEL Q1 Earnings Beat, 2025 Sales View Up as Cabometyx Drives Top Line
Exelixis' first-quarter earnings and sales beat estimates as lead drug Cabometyx maintains momentum. The company raises its sales guidance for 2025.
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas' Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting - Editas Medicine ( NASDAQ:EDIT )
Data demonstrate therapeutically relevant editing levels using a clinically validated strategy, supporting its development as a novel, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 ( GLOBE NEWSWIRE ) -- Editas Medicine, Inc.
Is Editas Medicine ( EDIT ) Stock Outpacing Its Medical Peers This Year?
Here is how Editas Medicine (EDIT) and Arbutus Biopharma (ABUS) have performed compared to their sector so far this year.
Editas Q1 Loss Narrower Than Expected, Revenues Increase Y/Y
EDIT announces encouraging first-quarter 2025 results, as both earnings and revenues beat estimates.
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting - Editas Medicine ( NASDAQ:EDIT )
In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice CAMBRIDGE, Mass., May 13, 2025 ( GLOBE NEWSWIRE ) -- Editas Medicine, Inc.
Editas Medicine ( EDIT ) Reports Q1 Loss, Tops Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of 15.69% and 385.21%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Editas ( EDIT ) Upgraded to Buy: What Does It Mean for the Stock?
Editas (EDIT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - Keros Therapeutics ( NASDAQ:KROS )
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
CAMBRIDGE, Mass., April 28, 2025 ( GLOBE NEWSWIRE ) -- Editas Medicine, Inc. ( Nasdaq: EDIT ) , a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual Meeting of the American Society of Gene ...
Editas Medicine to Present Preclinical Data Demonstrating Progress in the Development of an in vivo Gene Editing Pipeline at the American Society of Gene and Cell Therapy Annual Meeting - Editas Medicine ( NASDAQ:EDIT )
CAMBRIDGE, Mass., April 28, 2025 ( GLOBE NEWSWIRE ) -- Editas Medicine, Inc. EDIT, a pioneering gene editing company, today announced that five abstracts have been accepted for presentation, including one oral presentation, at the 28th Annual Meeting of the American Society of Gene and Cell ...
Why Is Editas ( EDIT ) Down 37.1% Since Last Earnings Report?
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics - GlycoMimetics ( NASDAQ:GLYC )
Jonathan McNeill, M.D., Appointed President and Chief Operating Officer Ellie Im, M.D., Appointed Chief Medical Officer Additional Leadership Appointments: Rick Scalzo, MBA, as Chief Financial Officer, and Amy Reilly, as Chief Communications Officer
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer - Dyne Therapeutics ( NASDAQ:DYN )
- Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation - WALTHAM, Mass., March 20, 2025 ( GLOBE NEWSWIRE ) -- Dyne Therapeutics, Inc.
Editas Q4 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
EDIT stock is down following the announcement of dismal fourth-quarter 2024 results as both earnings and revenues miss estimates.
Editas Medicine ( EDIT ) Reports Q4 Loss, Misses Revenue Estimates
Editas (EDIT) delivered earnings and revenue surprises of -41.03% and 19.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Editas Medicine Announces Fourth Quarter and Full Year 2024 Results and Business Updates
On track to declare two in vivo editing development candidates via gene upregulation, one in HSCs and one in liver, in mid-2025Company to present further in vivo HSC preclinical data and further in vivo preclinical data in one liver indication by year-endOn track to establish one additional ...
Mirum Pharmaceuticals, Inc. ( MIRM ) Reports Q4 Loss, Tops Revenue Estimates
Mirum Pharmaceuticals (MIRM) delivered earnings and revenue surprises of -81.48% and 2.40%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Peering Into Editas Medicine's Recent Short Interest - Editas Medicine ( NASDAQ:EDIT )
Editas Medicine's EDIT short percent of float has fallen 10.76% since its last report. The company recently reported that it has 17.09 million shares sold short, which is 26.22% of all regular shares that are available for trading.
Editas Medicine to Announce Fourth Quarter/Full Year 2024 Financial Results and to Participate in Investor Conferences in March
CAMBRIDGE, Mass., Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Editas Medicine, Inc. ( Nasdaq: EDIT ) , a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q4/Full Year 2024 financial results and business updates ...
PTC Therapeutics ( PTCT ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
PTC Therapeutics (PTCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Is Adagene ( ADAG ) Stock Outpacing Its Medical Peers This Year?
Here is how Adagene Inc. Sponsored ADR (ADAG) and Editas Medicine (EDIT) have performed compared to their sector so far this year.
JPMorgan Downgrades Editas Medicine, Says Focus Shift Sparks Investor Caution - Editas Medicine ( NASDAQ:EDIT )
Editas Medicine extends its cash runway to Q2 2027 while prioritizing in vivo gene editing programs. JPMorgan downgrades Editas to Underweight, citing unclear timelines and limited near-term catalysts. Get Monthly Picks of Market's Fastest Movers Editas Medicine Inc.
EDIT Stock Falls on Decision to End Reni-Cel Studies, Cut Workforce
Editas stock falls as it ends development of reni-cel for SCD and TDT following failed attempts to find a commercial partner. It plans to cut workforce by 65%.
Walmart To Rally Over 22%? Here Are 10 Top Analyst Forecasts For Friday - Broadcom ( NASDAQ:AVGO ) , AES ( NYSE:AES )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Barclays slashed the price target for The AES Corporation AES from $23 to $17.
This Toll Brothers Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Nordson ( NASDAQ:NDSN ) , Editas Medicine ( NASDAQ:EDIT )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Stifel analyst Dae Gon Ha downgraded the rating for Editas Medicine, Inc.
Texas Aligns with Trump's Bitcoin Strategy, Proposes Reserve with 5-Year Hold; Taiwan Semiconductor Projected to Dominate 67% of Foundry Market by 2025: IDC - Top Headlines Today While US Slept
Bitcoin's Tug-of-War Around $100,000: Where Does The BTC Price Go From Here? Shiba Inu Burns 13 Million Coins In 24 Hours: 'SHIB Chart Looks Primed For Launch Very Soon,' Says Trader Donald Trump Pledges To 'Do Something Great With Crypto'-Here's What He's Done So Far
Editas Medicine Realigns Strategy to Focus on In Vivo Gene Editing, Targets Human Proof Of Concept By 2026 - Editas Medicine ( NASDAQ:EDIT )
On Thursday, Editas Medicine Inc. EDIT announced a strategic realignment to focus on in vivo gene editing. In vivo refers to studies or experiments conducted on living organisms or cells instead of dead organisms or tissue extracts. The opposite of in vivo is in vitro, which means outside the ...
Editas Stock Rises on Updated Data From SCD Study of Reni-Cel
EDIT's stock gains on updated positive safety and efficacy data from the phase I/II/III RUBY study of its lead candidate, reni-cel, for severe SCD.
